Phase 1 multicenter, open-label study to establish the maximum tolerated dose (MTD) of two administration schedules of E7389 (eribulin) liposomal formulation in patients (pts) with solid tumors.
Zubairi, I Molife, L Lopez, J Ranson, Malcolm R El-Khouly, F Savulsky, C Reyderman, L Jia, Y Hutton, E
Zubairi, I
Molife, L
Lopez, J
Ranson, Malcolm R
El-Khouly, F
Savulsky, C
Reyderman, L
Jia, Y
Hutton, E
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2016
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Phase 1 multicenter, open-label study to establish the maximum tolerated dose (MTD) of two administration schedules of E7389 (eribulin) liposomal formulation in patients (pts) with solid tumors. 2016, 39: 206-206 Oncol Res Treat